| Business Summary | | Andrx
Corporation
formulates
and
commercializes
controlled-release
oral
pharmaceuticals
using
its
proprietary
drug
delivery
technologies.
Andrx
markets
and
sells
Cartia
XT
and
Diltia
XT,
its
generic
or
bioequivalent
versions
of
Cardizem
CD
and
Dilacor
XR.
Andrx
uses
its
proprietary
drug
delivery
technologies
and
formulation
skills
to
develop
bioequivalent
versions
of
selected
controlled-release
brand
name
pharmaceuticals;
and
brand
name
controlled-release
formulations
of
existing
immediate-release
or
controlled-release
drugs.
Andrx
is
also
developing
bioequivalent
versions
of
specialty
or
niche
pharmaceutical
products.
Through
its
distribution
operations,
Andrx
primarily
sells
bioequivalent
drugs
manufactured
by
third
parties
primarily
to
independent
pharmacies,
pharmacy
chains
which
do
not
maintain
their
own
central
warehousing
facilities,
pharmacy
buying
groups
and
physicians'
offices. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Andrx
Corporation
formulates
and
commercializes
controlled-release
oral
pharmaceuticals
using
the
Company's
proprietary
drug
delivery
technologies.
For
the
six
months
ended
6/30/01,
revenues
totaled
$338.2
million.
Net
income
applicable
to
Andrx
Group
totaled
$43.4
million.
Results
are
not
comparable
due
to
the
9/00
reorganization
of
the
company's
common
stock
into
two
new
classes
of
tracking
stocks.
The
two
classes
are
Andrx
Common
Stock
and
Cybear
Common
Stock. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Alan Cohen, 46 Co-Chairman,
CEO | $515K | -- | Chih-Ming Chen, Ph. D., 49 Co-Chairman | 513K | -- | Elliot Hahn, Ph.D., 56 Pres | 2.3M | $1.9M | Scott Lodin, 45 Exec.
VP, Gen. Counsel, Pres of Andrx Pharmaceuticals | 4.8M | 4.4M | Angelo Malahias, 39 VP,
CFO | 2.6M | 2.4M | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|